{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:47:09Z","timestamp":1793677629551,"version":"4.5.1"},"reference-count":47,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Emerging long-term data indicate relapse rates of &amp;gt;50% after CD19-redirected chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory (R\/R) B-cell non-Hodgkin lymphoma (B-NHL). To reduce selective pressure on the CD19 antigen, we conducted a first-in-human phase 1 clinical trial of zamtocabtagene autoleucel (zamto-cel), a noncryopreserved tandem CD20-CD19\u2013directed CAR T-cell therapy. Two predefined dose levels (dose level 1 [DL1], 1 \u00d7 106 and DL2, 2.5 \u00d7 106 CAR+ T cells per kg bodyweight) were applied. The primary end point (EP) was the maximum tolerated dose (MTD). Secondary EPs included adverse events, best overall response (BOR), and biomarker assessments. A total of 12 patients, 6 patients per DL, were treated. No dose-limiting toxicity and no cytokine release syndrome or immune effector cell\u2013associated neurotoxicity syndrome of grade \u22653 were observed. Thus, MTD was not reached. The BOR by investigator assessment was 75%, with 5 of 12 patients (42%) achieving complete remission (CR) until month 12 with no relapse in clinical evaluation up to 5 years after infusion. CR was associated with a higher mean maximum observed concentration of zamto-cel and detection of zamto-cel beyond month 6. Additional product characterization revealed increased expression of CD27 and CD127 along with increased expansion of CAR+ central memory T cells in patients with CR, facilitating persistence and improved outcomes in R\/R B-NHL treated with zamto-cel. Based on the promising risk-to-benefit ratio, evaluation of zamto-cel at DL2 is ongoing in pivotal phase 2 clinical trials for patients with R\/R aggressive B-NHL. This trial was registered at www.ClinicalTrials.gov as NCT03870945.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018073","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T21:00:06Z","timestamp":1767992406000},"page":"2395-2405","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Zamtocabtagene autoleucel in relapsed\/refractory B-NHL: 5-year follow-up of a CD20\/19 tandem CAR T-cell phase 1 trial"],"prefix":"10.1182","volume":"10","author":[{"given":"Hyatt","family":"Balke-Want","sequence":"first","affiliation":[{"name":"1Cologne Lymphoma Working Group, Department of Internal Medicine I, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany"},{"name":"2Cancer Research Center Cologne Essen, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany"},{"name":"3Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7887-8313","authenticated-orcid":false,"given":"Philipp","family":"G\u00f6del","sequence":"additional","affiliation":[{"name":"1Cologne Lymphoma Working Group, Department of Internal Medicine I, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schmid","sequence":"additional","affiliation":[{"name":"4II. Medizinische Klinik H\u00e4matologie\/Onkologie, Universit\u00e4tsklinikum Augsburg, Augsburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Ayuk","sequence":"additional","affiliation":[{"name":"5Department of Stem Cell Transplantation, Universit\u00e4tsklinikum Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birte","family":"Friedrichs","sequence":"additional","affiliation":[{"name":"6Centrum f\u00fcr Integrierte Onkologie, Universit\u00e4tsklinikum D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl","family":"van Heteren","sequence":"additional","affiliation":[{"name":"7Miltenyi Biomedicine GmbH, Bergisch Gladbach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Holtkamp","sequence":"additional","affiliation":[{"name":"7Miltenyi Biomedicine GmbH, Bergisch Gladbach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Zadoyan","sequence":"additional","affiliation":[{"name":"7Miltenyi Biomedicine GmbH, Bergisch Gladbach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Brillant","sequence":"additional","affiliation":[{"name":"7Miltenyi Biomedicine GmbH, Bergisch Gladbach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Costa","sequence":"additional","affiliation":[{"name":"7Miltenyi Biomedicine GmbH, Bergisch Gladbach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Hanssens","sequence":"additional","affiliation":[{"name":"7Miltenyi Biomedicine GmbH, Bergisch Gladbach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Holzer","sequence":"additional","affiliation":[{"name":"8Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1394-1024","authenticated-orcid":false,"given":"Christian","family":"W\u00f6hle","sequence":"additional","affiliation":[{"name":"8Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Biedermann","sequence":"additional","affiliation":[{"name":"8Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"B\u00fcrger","sequence":"additional","affiliation":[{"name":"8Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimas","family":"Orentas","sequence":"additional","affiliation":[{"name":"9Lentigen Technology Inc, Gaithersburg, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toon","family":"Overstijns","sequence":"additional","affiliation":[{"name":"7Miltenyi Biomedicine GmbH, Bergisch Gladbach, Germany"},{"name":"8Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6539-226X","authenticated-orcid":false,"given":"Christoph","family":"Scheid","sequence":"additional","affiliation":[{"name":"10Leukapheresis and Stem Cell Transplant Unit, Department of Internal Medicine I, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Holtick","sequence":"additional","affiliation":[{"name":"10Leukapheresis and Stem Cell Transplant Unit, Department of Internal Medicine I, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Miltenyi","sequence":"additional","affiliation":[{"name":"7Miltenyi Biomedicine GmbH, Bergisch Gladbach, Germany"},{"name":"8Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7425-4455","authenticated-orcid":false,"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[{"name":"1Cologne Lymphoma Working Group, Department of Internal Medicine I, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany"},{"name":"2Cancer Research Center Cologne Essen, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[{"name":"1Cologne Lymphoma Working Group, Department of Internal Medicine I, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9559-8575","authenticated-orcid":false,"given":"Nadine","family":"Kutsch","sequence":"additional","affiliation":[{"name":"1Cologne Lymphoma Working Group, Department of Internal Medicine I, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"issue":"2","key":"2026041408011225200_bib2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"14","key":"2026041408011225200_bib3","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"19","key":"2026041408011225200_bib4","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"6537","key":"2026041408011225200_bib5","doi-asserted-by":"crossref","first-page":"eaba1786","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"issue":"7949","key":"2026041408011225200_bib6","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"issue":"19","key":"2026041408011225200_bib1","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2026041408011225200_bib7","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","article-title":"Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma","volume":"28","author":"Scholler","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"2026041408011225200_bib8","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41591-023-02754-1","article-title":"Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma","volume":"30","author":"Locke","year":"2024","journal-title":"Nat Med"},{"issue":"8","key":"2026041408011225200_bib9","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.ccell.2025.05.013","article-title":"CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma","volume":"43","author":"Stahl","year":"2025","journal-title":"Cancer Cell"},{"issue":"12","key":"2026041408011225200_bib10","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"issue":"5","key":"2026041408011225200_bib11","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the antigen density requirement for CAR T-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov"},{"issue":"10","key":"2026041408011225200_bib12","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"issue":"10","key":"2026041408011225200_bib13","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","article-title":"CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial","volume":"27","author":"Cordoba","year":"2021","journal-title":"Nat Med"},{"issue":"8","key":"2026041408011225200_bib14","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"issue":"10","key":"2026041408011225200_bib15","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"issue":"1","key":"2026041408011225200_bib16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40425-017-0246-1","article-title":"A tandem CD19\/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines","volume":"5","author":"Schneider","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"14","key":"2026041408011225200_bib17","first-page":"1632","article-title":"Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma","volume":"136","author":"Tong","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2026041408011225200_bib18","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1158\/2159-8290.CD-22-0964","article-title":"CD19\/CD20 bispecific chimeric antigen receptor (CAR) in naive\/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma","volume":"13","author":"Larson","year":"2023","journal-title":"Cancer Discov"},{"issue":"8","key":"2026041408011225200_bib19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J"},{"issue":"3","key":"2026041408011225200_bib20","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1182\/blood-2010-05-286286","article-title":"Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy","volume":"117","author":"Hinrichs","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2026041408011225200_bib21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.immuni.2014.05.018","article-title":"Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8+ central memory T cells","volume":"41","author":"Graef","year":"2014","journal-title":"Immunity"},{"issue":"5","key":"2026041408011225200_bib22","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"12","key":"2026041408011225200_bib23","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"issue":"9","key":"2026041408011225200_bib24","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1158\/2159-8290.CD-22-1276","article-title":"A novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development","volume":"13","author":"Dickinson","year":"2023","journal-title":"Cancer Discov"},{"issue":"5","key":"2026041408011225200_bib25","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/80877","article-title":"CD27 is required for generation and long-term maintenance of T cell immunity","volume":"1","author":"Hendriks","year":"2000","journal-title":"Nat Immunol"},{"issue":"2","key":"2026041408011225200_bib26","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.immuni.2024.01.011","article-title":"Signaling via a CD27-TRAF2-SHP-1 axis during naive T cell activation promotes memory-associated gene regulatory networks","volume":"57","author":"Jaeger-Ruckstuhl","year":"2024","journal-title":"Immunity"},{"issue":"5","key":"2026041408011225200_bib27","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1172\/JCI200523134","article-title":"Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool","volume":"115","author":"Melchionda","year":"2005","journal-title":"J Clin Invest"},{"issue":"17","key":"2026041408011225200_bib28","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1182\/blood-2009-09-241398","article-title":"IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell\u2013mediated rejection of systemic lymphoma in immunodeficient mice","volume":"115","author":"Markley","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2026041408011225200_bib29","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1158\/2159-8290.CD-17-0538","article-title":"Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells","volume":"7","author":"Shum","year":"2017","journal-title":"Cancer Discov"},{"issue":"27","key":"2026041408011225200_bib30","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026041408011225200_bib31","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","year":"2017"},{"issue":"4","key":"2026041408011225200_bib32","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"2026041408011225200_bib33","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/ni1565","article-title":"Transcription factor KLF2 regulates the migration of naive T cells by restricting chemokine receptor expression patterns","volume":"9","author":"Sebzda","year":"2008","journal-title":"Nat Immunol"},{"issue":"13","key":"2026041408011225200_bib34","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1182\/bloodadvances.2020001696","article-title":"Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma","volume":"4","author":"Rushton","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"2026041408011225200_bib35","doi-asserted-by":"crossref","first-page":"e004185","DOI":"10.1136\/jitc-2021-004185","article-title":"To go or not to go? Biological logic gating engineered T cells","volume":"10","author":"Abbott","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"2","key":"2026041408011225200_bib36","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","article-title":"Rapid manufacturing of non-activated potent CAR T cells","volume":"6","author":"Ghassemi","year":"2022","journal-title":"Nat Biomed Eng"},{"issue":"2","key":"2026041408011225200_bib37","doi-asserted-by":"crossref","first-page":"101250","DOI":"10.1016\/j.omtm.2024.101250","article-title":"CAR-T cell manufacturing landscape\u2014lessons from the past decade and considerations for early clinical development","volume":"32","author":"Dias","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"2026041408011225200_bib38","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"24","key":"2026041408011225200_bib39","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2026041408011225200_bib40","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas dos Santos","year":"2024","journal-title":"Nat Med"},{"issue":"4","key":"2026041408011225200_bib41","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"issue":"12","key":"2026041408011225200_bib42","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/ajh.26718","article-title":"Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells","volume":"97","author":"Zurko","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"2026041408011225200_bib43","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41375-021-01345-8","article-title":"Long-term activity of tandem CD19\/CD20 CAR therapy in refractory\/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"2026041408011225200_bib44","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/blood-2011-03-344275","article-title":"CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo","volume":"119","author":"Song","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2026041408011225200_bib45","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nri2970","article-title":"Harnessing the biology of IL-7 for therapeutic application","volume":"11","author":"Mackall","year":"2011","journal-title":"Nat Rev Immunol"},{"issue":"23","key":"2026041408011225200_bib46","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1200\/JCO.23.02019","article-title":"Phase I trial of GD2.CART cells augmented with constitutive interleukin-7 receptor for treatment of high-grade pediatric CNS tumors","volume":"42","author":"Lin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026041408011225200_bib47","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41590-020-0714-5","article-title":"Dynamics in protein translation sustaining T cell preparedness","volume":"21","author":"Wolf","year":"2020","journal-title":"Nat Immunol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/7\/2395\/2512017\/blooda_adv-2025-018073-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/7\/2395\/2512017\/blooda_adv-2025-018073-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T12:01:22Z","timestamp":1776168082000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/7\/2395\/565941\/Zamtocabtagene-autoleucel-in-relapsed-refractory-B"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,4,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018073","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,14]]},"published":{"date-parts":[[2026,4,1]]}}}